Fulacimstat - Bayer Healthcare

Drug Profile

Fulacimstat - Bayer Healthcare

Alternative Names: BAY 1142524

Latest Information Update: 27 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Class Benzoxazoles; Heart failure therapies; Pyrimidines; Small molecules
  • Mechanism of Action Chymase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Kidney disorders; Left ventricular dysfunction; Type 2 diabetes mellitus

Most Recent Events

  • 04 Sep 2018 Bayer completes the phase II CHIARA MIA 2 trial in Left ventricular dysfunction (Adjunctive treatment, In the elderly, In adults) in Spain, Germany, Czech Republic, Israel and Italy (PO) (NCT02976467)
  • 01 Jun 2018 Chemical structure information added
  • 12 Feb 2018 Phase-I clinical trials in Kidney disorders in Germany (PO) (NCT03402438)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top